Abstract
Neonatal infections caused by GBS are commonly associated with a deficiency of IgG antibody to the type-specific polysaccharide of the infecting organism. The prevalence and importance of human antibody to specific surface proteins, which are very common in clinical GBS strains, are unknown. Type-specific antibody is sufficiently prevalent that immunoglobulin preparations for both intramuscular and intravenous use contain animal-protective, opsonic antibody for many GBS strains. The availability of polysaccharide vaccines suggest that even more potent, "hyperimmune" preparations can be prepared from immunized volunteers. The importance of selective antibody deficiency in K1 E. coli infections of newborns is less clear. Protective, opsonic antibody is more difficult to demonstrate in human serum, but activity has been shown in some IGIV preparations. The specificity of the active antibody and the feasibility of producing hyperimmune IGIV against K1 E. coli are unknown at this time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
